from Breakingviews:

Valeant may strain to engineer way out the in door

June 6, 2016

The author is a Reuters Breakingviews columnist. The opinions expressed are his own.

from Breakingviews:

J&J’s corpulence defense weighs heavy

June 2, 2016

The author is a Reuters Breakingviews columnist. The opinions expressed are his own. 

from Breakingviews:

Bayer’s Monsanto bid yields poor financial harvest

May 27, 2016

The author is a Reuters Breakingviews columnist. The opinions expressed are his own.

from Breakingviews:

Medical firms’ $18 bln merger lacks clear logic

May 3, 2016

The author is a Reuters Breakingviews columnist. The opinions expressed are his own.

from Breakingviews:

Abbott’s $25 bln buy inspires little investor hope

April 28, 2016

The author is a Reuters Breakingviews columnist. The opinions expressed are his own.

from Breakingviews:

Valeant plays chicken with death spiral

March 15, 2016

The author is a Reuters Breakingviews columnist. The opinions expressed are his own.

from Breakingviews:

Valeant CEO back with less power and no glory

February 29, 2016

The author is a Reuters Breakingviews columnist. The opinions expressed are his own.

from Breakingviews:

Overdue Mylan deal is not the one investors wanted

February 11, 2016

The author is a Reuters Breakingviews columnist. The opinions expressed are his own. 

from Breakingviews:

Glaxo self-help looks better than surgeon’s knife

February 3, 2016

The author is a Reuters Breakingviews columnist.  The opinions expressed are his own.

from Breakingviews:

Alere board’s diligence brings 51 pct premium

February 1, 2016

The author is a Reuters Breakingviews columnist. The opinions expressed are his own.